Injectable anabolic androgenic steroid
Masteron propionate
Drostanolone is prohibited at all times by WADA when administered exogenously.1 Half-life, bioavailability, time to peak and typical dose are the app's figures; no cited source gives them.
Masteron propionate after one dose: 50% at ~2.5 days, 25% at 5 days, 12.5% at 7.5 days.
Drawn from the half-life in the app's model, ~2.5 days. The model's figures
- Compound
- Masteron propionate
- Symbol
- MSP
- Family
- Other steroids
- Parts
- 16
- References
- 35
- Checked
- Last reviewed . Sources are listed below.
Overview
Borodi and colleagues (National Institute For R&D of Isotopic and Molecular Technologies, Cluj-Napoca, Romania), in Molecules in 2020, write that "2α-Methyl-4,5α-dihydrotestosterone 17β-propionate, known as drostanolone propionate or masteron, is a synthetic anabolic-androgenic steroid derived from dihydrotestosterone".2 Papers from 1962 to 1975 name it drostanolone propionate (Masteril, Masterid), dromostanolone propionate (NSC-12198) or 2alpha-methyldihydrotestosterone propionate.3,4,5,6
Tauchen and colleagues, in Molecules in 2021, call drostanolone "another agent that has been removed from medicinal use, although it was of value in certain types of breast cancer", and their table lists "Breast cancer (now discontinued in most countries)" for drostanolone with a "Propionate ester (intramuscular injection)".7 A search of DailyMed by drug name on 16 November 2026 returned 0 labels for drostanolone, dromostanolone and masteron.35
The human studies cited below date from 1962 to 1987 and are mostly in breast cancer; the other sources are product tests, case reports, two small observational studies and laboratory papers. None of the cited sources reports a half-life, bioavailability or time to peak for drostanolone propionate. The Moderate Evidence badge shown with this compound is the app's own grade and not a conclusion of the sources; most of the dated human papers cited are breast cancer records, and none gives a dose in its PubMed record.
How it works
Sources in this part
Tauchen and colleagues write that "every anabolic steroid retains some androgenic activity" and list a methyl substitution at the C2 position, as in drostanolone, among the chemical changes by which anabolic activity may be increased.7 Bond and colleagues, in Frontiers in Endocrinology in 2022, list drostanolone among commonly used anabolic androgenic steroids (AAS) that are "already 5α-reduced".8
De Boer and colleagues (Netherlands Institute for Drugs and Doping Research, Utrecht), in the Journal of Steroid Biochemistry and Molecular Biology in 1992, identified 2 alpha-methyl-androsterone as the major metabolite of drostanolone and report that "All metabolites were found to be conjugated to glucuronic acid".9 Gauthier and colleagues, in Steroids in 2009, incubated drostanolone with cryopreserved human hepatocytes, identified "the common 3alpha- (major) and 3beta-reduced metabolites", and report that the metabolites from the cultures were present, in different relative amounts, in urine collected after administration to a human volunteer.10
Half-life and pharmacokinetics
Values from the Milligram app's model.
- Half-life
- ~2.5 days
- Bioavailability
- 95%
- Typical dose
- 150–500 mg/week
- Route
- IM
- Time to peak
- ~18 h
The app's figures for drostanolone propionate are a half-life of ~2.5 days (60 hours), a bioavailability of 95%, a time to peak of ~18 h, an intramuscular route and a typical dose of 150–500 mg/week. None of the cited sources reports a half-life, bioavailability or time to peak for drostanolone propionate, as the table shows.
| Measure | App figure | Source figure |
|---|---|---|
| Half-life | ~2.5 days (60 h) | None of the cited sources reports a half-life for drostanolone propionate. For testosterone, Bond and colleagues state that unmodified testosterone "reportedly has a half-life of approximately 10 minutes when injected" and that propionate or enanthate esterification prolongs it to approximately 1.0 and 4.2 days, which concerns testosterone esters and not drostanolone propionate.8 |
| Detection time after injection | Not an app figure | Liu and colleagues report two metabolites detectable for up to 24 days by liquid-liquid extraction and 7 days by direct-injection analysis after intramuscular injection of drostanolone to one volunteer; these are detection windows and not a half-life, and the record does not name the ester or the dose.11 |
| Bioavailability | 95% | None of the cited sources reports a bioavailability for drostanolone propionate. |
| Time to peak | ~18 h | None of the cited sources reports a time to peak for drostanolone propionate. |
| Route | IM | Tauchen and colleagues list the propionate ester of drostanolone as an intramuscular injection, and Baranov and colleagues list IM for their patient's drostanolone propionate.7,12 |
| Typical dose | 150–500 mg/week | None of the cited sources gives a typical dose; the amounts reported in the doses table run from 200 mg a week (Ozkurt and colleagues) to 300–700 mg/week (Baranov and colleagues), and 100–150 mg every other day (Wiacek and colleagues). |
The chart below is an illustration from a one-compartment model that uses the app's half-life of 60 hours and time to peak of 18 hours, with an injection every other day, an interval that Wiacek and colleagues list for drostanolone propionate in a table of drugs used by their competitors without stating how many used it, while Safizadeh Shabestari and colleagues report four times per week.13,24
Level over 3 weeks
Level, as a share of the peak after one 100 mg dose
As studied: every other day13.
An illustration from a pharmacokinetic model using a half-life of 60 hours (2.5 days). It is not a measured level or a suggested dose.
Human studies
The papers below are trials in breast cancer, except one set of case reports in aplastic anemia. None of their PubMed records gives a dose.
| Study and year | Design | People | Dose and length | Main result |
|---|---|---|---|---|
| Bennett, Helman and Palmer, 19756 | Drostanolone propionate (Masteril) against oophorectomy, nandrolone phenylpropionate (Durabolin) and ethinyl oestradiol in three menopausal groups, 1968 to 1972; PubMed lists a randomized controlled trial. | Patients with breast cancer in three menopausal groups; numbers not in the PubMed record. | Not given in the PubMed record. | Responded: premenopausal 44% on Masteril and 22% on oophorectomy; perimenopausal 34,5% on Masteril and 39% on Durabolin; postmenopausal 57% on oestrogens and 38,5% on Masteril. |
| Clavel and colleagues, 198214 | Randomized: tamoxifen with drostanolone propionate, CMF chemotherapy, or both. | 98 post-menopausal women with breast cancer. | Not given in the PubMed record. | Hormonal therapy alone gave the best immediate objective responses, the least adverse side-effects and possibly improved survival rates. |
| Rieche and Wolff, 197515 | Randomized; single hormone therapy, then cyclophosphamide added; drostanolone, ester not named. | Metastatic breast cancer; number not given. | Not given; observation 10 to 16 weeks. | Similar objective response rates for testosterone decanoate, drostanolone and testosterone; with cyclophosphamide, testosterone decanoate and testolactone did better than drostanolone; the combination raised objective responses from 22-25 percent to 46-55 percent. |
| Wolff and Rieche, 197816 | Controlled; testololactone, drostanolone, nandrolone; cyclophosphamide added after 4 weeks; ester not named. | 91 patients with advanced breast cancer. | Not given; remissions after 4 and 16 weeks. | No difference between the three drugs; average remission rate 24% after 4 weeks and 46% after 16 weeks, the second interval with cyclophosphamide. |
| Azen and Shahidi, 197717 | Case reports in acquired aplastic anemia, mainly oxymetholone; dromostanolone, ester not named. | 3 patients; dromostanolone result for two. | Not given in the PubMed record. | No hematologic response to dromostanolone in two patients. |
Deeper analysis: Bennett and colleagues, South African Medical Journal, 1975
Bennett, Helman and Palmer tested drostanolone propionate (Masteril) between 1968 and 1972 against oophorectomy in premenopausal patients, nandrolone phenylpropionate in a perimenopausal group and ethinyl oestradiol in a postmenopausal group.6 They conclude that Masteril "may appear to be less effective than oestrogens in the postmenopausal patients".6 The PubMed record gives no group sizes, doses, funding statement, author ties to a sponsor or stated limitations, so the percentages cannot be set against numbers of patients.6
Deeper analysis: Clavel and colleagues, La Semaine des Hopitaux, 1982
Clavel and colleagues randomized 98 post-menopausal women to tamoxifen with drostanolone propionate (n = 34), CMF chemotherapy (n = 30) or both (n = 34), and state that "Hormonal receptors had not been assayed in any patient" and that the results "are in favour of hormonal therapy alone".14 The hormonal arm combined tamoxifen with drostanolone propionate, so the result does not isolate drostanolone propionate, and the PubMed record gives no response rates, doses, funding statement or stated limitations.14
Further breast cancer papers with titles only
The PubMed records of eight further papers on drostanolone or dromostanolone propionate in breast cancer carry a title and no summary text, among them a "Triple-blind study of 68 patients treated with dromostanolone and fluorometholone" (Gaertner and colleagues, 1968), "Report on 22 treated cases" (Poddig-von Riegen, 1971) and a comparison with nandrolone decanoate (Deca-durabolin) (Chowdhury and colleagues, 1976).3,18,19,4,20,5,21,22
Doses reported in studies
The app's typical dose is 150–500 mg/week. None of the cited trials gives a dose for drostanolone propionate in its PubMed record, and the amounts below were reported by people using it outside medical care, in two observational studies and two case reports, and not tested in a trial.
| Study and year | People | Amount reported for drostanolone propionate |
|---|---|---|
| Wiacek and colleagues, 202313 | 8 male bodybuilders aged 30 to 35 over a 6-month competition preparation; amounts self-administered, from the competitors' notes. | 100–150 mg every other day (q.o.d.) in months 1 to 5, listed with testosterone propionate 100–150 mg q.o.d., trenbolone acetate and other drugs. |
| Ozkurt and colleagues, 202323 | 12 bodybuilders using AAS and diet supplements; 8 of them listed drostanolone propionate. | 200 mg a week in 5 of them, 300 mg in 2 and 500 mg in 1, each alongside other AAS. |
| Baranov and colleagues, 202612 | One man followed for eight years; regimens reconstructed from his personal records. | IM 300–700 mg/week for 2 months (4.3 g), 3 months (7.4 g) and 5 months (10.0 g) in three cycles, 21.7 g in all. |
| Safizadeh Shabestari and colleagues, 202224 | One 31-year-old man with acute pancreatitis. | "Masteron four times per week (drostanolone propionate)", with no amount per injection in the passage that lists the drugs taken. |
Side effects reported
Bennett and colleagues state that "The side-effects of Masteril are generally not serious and rarely contra-indicate its use", and the PubMed record lists no individual side effects or rates.6 Clavel and colleagues report the least adverse side-effects in the hormonal arm (tamoxifen with drostanolone propionate) compared with chemotherapy or both, without rates in the PubMed record.14 The PubMed records of four cited breast cancer papers (Helman and Bennett, 1972; Poddig-von Riegen, 1971; Chowdhury and colleagues, 1976; Wolff and Rieche, 1978) are indexed under the MeSH term virilism, an indexing label and not a reported result, and none of the four gives a number of cases.19,20,21,16
Case reports with several drugs
Safizadeh Shabestari and colleagues, in the Journal of Medical Case Reports in 2022, describe a 31-year-old bodybuilder with acute pancreatitis a month after starting a combination that included "Masteron four times per week (drostanolone propionate)", other steroids, growth hormone and clenbuterol.24 The authors give the combination as the most likely etiology of the pancreatitis, call this "the first case report on the potential toxicity of" the listed drugs "to the pancreas", and report that after avoiding them he "had no further episodes of pancreatitis during 1 year of follow-up", a period that the report's timeline table gives as 2 years.24 The report was supported by a university publication fund, and the authors declare no competing interests.24
Baranov and colleagues (Sechenov University, Moscow), in the Journal of Clinical Medicine in 2026, report a man first assessed at 26 after 33 cumulative months of AAS use, with what they call severe AAS-associated cardiomyopathy (palpitations, ventricular ectopic beats, severe concentric left ventricular hypertrophy with a septum of 22 mm, a posterior wall of 21 mm and a left ventricular mass of 551 g, and an enlarged right atrium), whose left ventricular mass index fell from 261 to 111 g/m² over eight years after he stopped all agents.12 His cycles included drostanolone propionate with other steroids, and the authors write that "the regression cannot be attributed to AAS cessation in isolation" because growth hormone was also withdrawn, training load fell and body weight fell by 20 kg; they report regimens "reconstructed from contemporaneous personal records", no external funding and no conflicts of interest.12
Gheddar and colleagues, in the Journal of Analytical Toxicology in 2023, describe a 29-year-old man found dead at home after an "unremarkable autopsy with normal histology"; blood tested positive for testosterone, boldenone, stanozolol and trenbolone, and his head hair held drostanolone at 112-30 pg/mg, drostanolone enanthate at 26-5 pg/mg and drostanolone propionate at 15-4 pg/mg among several steroids; the experts concluded that "the manner of death can be listed as toxic due to massive repetitive use of anabolic steroids during the previous months", a conclusion about the combination.25
Bloodwork and markers
Sources in this part
The app lists total testosterone, free testosterone, estradiol, hematocrit, lipids and PSA as markers to monitor for drostanolone propionate. None of the cited sources reports a change in any of them attributed to drostanolone propionate alone. In the single patient of Baranov and colleagues, four blood tests taken during a final 14-month cycle that included drostanolone propionate for 5 months, with other steroids and growth hormone, listed SHBG of 2.2 to 5.5 nmol/L (reference 13 to 71) and ALT of 109 to 177 U/L (reference below 41), which do not isolate drostanolone propionate.12
Wiacek and colleagues (Gdansk University of Physical Education and Sport, Poland, and the Botswana University of Agriculture and Natural Resources), in the International Journal of Sports Medicine in 2023, followed 8 male bodybuilders aged 30 to 35, all of whom had used performance-enhancing drugs for more than five years, through six months of competition preparation, with a table that lists drostanolone propionate among the drugs used by the competitors.13 They report that mean triglycerides "fluctuated between borderline high and high", mean HDL cholesterol "remained within the low range", LDL cholesterol fluctuating between near-optimal or above-optimal, borderline high and high levels, AST and ALT "remained within the high concentration" range, and the blood nitrogen urea concentration "fluctuated between normal and elevated levels".13 The authors conclude that the drugs "do not have an immediate detrimental impact" on the parameters studied, and list as limitations "the small study sample and the lack of clinical control over the quality of drugs used by competitors".13 The study was funded by the participants and the authors, and the authors declare no conflict of interest.13
Ozkurt and colleagues, in Cureus in 2023, compared 12 bodybuilders using AAS and diet supplements, 8 of whom listed drostanolone propionate, with 12 using supplements only, and report that "urinary albumin and protein excretion were considerably higher" in the AAS group.23 Creatinine-based eGFR was similar in the two groups (119.67 and 122.08 ml/min, p = 0.426), while cystatin-based eGFR was lower in the AAS group (120.67 and 122.08 ml/min, p = 0.039).23 Half of the AAS group smoked and none of the supplement-only group did, and the AAS group also had higher AST, ALT and creatine kinase (p < 0.001 for each).23 They describe the findings as a "potential link between early kidney damage and the direct use of AAS" that "requires further investigation", and name the low number of participants as a limitation.23
Detection in testing
Liu and colleagues (Peking University Health Science Center and the National Anti-Doping Laboratory of the China Anti-Doping Agency), in Steroids in 2016, state that "Drostanolone is one of the most frequently detected anabolic androgenic steroids in doping control analysis".11 They confirmed eleven metabolites in the urine of one healthy male volunteer and propose two as markers detectable for up to 24 days by liquid-liquid extraction and 7 days by direct-injection analysis after intramuscular injection.11 Albertsdóttir and colleagues, in Drug Testing and Analysis in 2020, ran two excretion studies of drostanolone, funded by the Partnership for Clean Competition, and report the routinely monitored main metabolite detectable for up to 29 days and a sulfated metabolite for up to 24 days; the PubMed record does not name the ester.26
In hair, Gheddar and colleagues report drostanolone propionate at 15-4 pg/mg in a death case, and Kintz and colleagues, in the Journal of Forensic Sciences in 2021, report drostanolone at 8 and 11 pg/mg in nail clippings among six authentic cases of abuse, with concentrations "always in the low pg/mg range".25,27 Favretto and colleagues, in Drug Testing and Analysis in 2022, report the main drostanolone metabolite at 202 ng/ml in the urine of a bodybuilder found dead, alongside clenbuterol and other steroids.28
What tested products contained
Sources in this part
Deeper analysis: Balayssac and colleagues, Molecules, 2025
Balayssac and colleagues (University of Toulouse, France) analysed anabolic steroid formulations seized by French law enforcement authorities, first 20 formulations by 1H NMR and then 12 oil-based injectable formulations by 13C NMR.29 One injectable, sample OI-8, was labelled with testosterone propionate 100, trenbolone acetate 100 and drostanolone propionate 100 (mg/mL), and the analysis detected only testosterone propionate, at 49 ± 1 mg/mL or 49% of the claimed amount.29 Across the 12 injectables the authors write that "all the twelve analyzed injectable formulations were of poor quality, with a mismatch between the advertised and actual contents", and report no correlation of the 12 formulations with the drostanolone pattern (Pearson coefficient below −0.03), against above 0.65 for the testosterone moiety.29 The authors report no external funding and no conflicts of interest, and they write that the chemometric approach, "although tested on a limited number of samples, faces limitations in terms of statistical significance and generalizability".29
Ribeiro and colleagues (São Paulo State University, Brazil), in Steroids in 2018, analysed 40 samples of injectable and capsule anabolic drugs by 1H NMR, listed drostanolone propionate among the active ingredients on the samples, and report that eight of the 40 "did not show the presence of the active principle stated on the label", without naming which products, or how many were labelled drostanolone propionate, in the PubMed record.30 The PubMed record is tagged "Research Support, Non-U.S. Gov't".30
Animal and cell studies
Sources in this part
The results in this section are from rats and cells, not people. Teller and colleagues, in Cancer Research in 1982, treated established rat mammary carcinomas for 4 weeks with 2 alpha-methyldihydrotestosterone propionate (MDTP) and report 15 to 48% tumor complete remission at 1.25 to 5 mg/kg/day, against 21% with 5-fluorouracil alone at 17.5 mg/kg/day and 3% at 8 mg/kg/day, and 96, 91 and 75% with MDTP at 5, 2.5 and 1.25 mg/kg/day combined with 5-fluorouracil at 17.5 mg/kg/day, which they describe as "marked synergism"; the PubMed record is tagged "Research Support, U.S. Gov't, P.H.S.".31 Fujita and colleagues, in 1983, report growth inhibitions of 16-94% by MDTP at 0.36-360.5 micrograms/ml in human MCF-7 breast carcinoma cells in vitro.32
Regulatory and anti-doping status
The World Anti-Doping Agency's 2026 Prohibited List, in force from 1 January 2026, places anabolic agents under "ANABOLIC AGENTS PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION)" and names drostanolone among the anabolic androgenic steroids in S1.1 "when administered exogenously".1 The list does not name an ester of drostanolone; the S1.1 entry ends with "and other substances with a similar chemical structure or similar biological effect(s) including their esters", and the list's index has an entry "Esters of anabolic androgenic steroids".1 The list states that all prohibited substances in the class are non-Specified Substances.1
In the United States, 21 CFR 1308.13(f) places any substance meeting the definition of an anabolic steroid in Schedule III, including any preparation containing any quantity of "the following substances, including its salts, esters and ethers", and the list includes "(28) drostanolone (17β-hydroxy-2α-methyl-5α-androstan-3-one)", unless specifically excepted or listed in another schedule.33 Tauchen and colleagues list drostanolone's breast cancer use as "now discontinued in most countries".7
What is not known
Sources in this part
- The half-life, bioavailability and time to peak of drostanolone propionate are not reported in the cited sources.
- None of the cited sources compares drostanolone propionate with drostanolone enanthate, or isolates its effect on aromatase or on sex hormone-binding globulin.
- A 1977 paper by Trams in the European Journal of Cancer is titled "Effect of drostanolone propionate on the binding of oestradiol and dihydrotestosterone by normal and malignant target tissues", and its PubMed record gives no summary text.34
Frequently asked questions
Sources in this part
What is the half-life of drostanolone propionate?
The app gives drostanolone propionate a half-life of ~2.5 days (60 hours), and none of the cited sources reports a half-life for it. In one volunteer given drostanolone by intramuscular injection, two metabolites were detectable for up to 24 days by liquid-liquid extraction and 7 days by direct-injection analysis, which are detection windows and not a half-life.11
Is drostanolone propionate banned by WADA?
Drostanolone is named on the WADA 2026 Prohibited List among the anabolic androgenic steroids in S1.1 "when administered exogenously", and anabolic agents are prohibited at all times; the list does not name the propionate ester, and S1.1 ends with "including their esters".1
Is drostanolone propionate a controlled substance in the US?
Drostanolone is listed in 21 CFR 1308.13(f) among the Schedule III anabolic steroids, and the entry covers the listed substances "including its salts, esters and ethers", unless specifically excepted or listed in another schedule.33
What is Masteron propionate?
Masteron is a name given for drostanolone propionate, 2α-methyl-4,5α-dihydrotestosterone 17β-propionate, which Borodi and colleagues describe as a synthetic anabolic-androgenic steroid derived from dihydrotestosterone.2
What was drostanolone propionate used for in medicine?
Is there a drug label for drostanolone propionate?
A search of DailyMed by drug name on 16 November 2026 returned 0 labels for drostanolone, dromostanolone and masteron.35
How long is drostanolone detectable in urine?
In one healthy male volunteer given drostanolone by intramuscular injection (the record names neither the ester nor the dose), two proposed biomarker metabolites were detected for up to 24 days by liquid-liquid extraction and 7 days by direct-injection analysis.11 Albertsdóttir and colleagues report up to 29 days for the routinely monitored main metabolite after hydrolysis of the glucuronide with E. coli-derived β-glucuronidase, in two excretion studies with the ester not named.26
What have tests of products labelled drostanolone propionate shown?
One seized injectable labelled with testosterone propionate, trenbolone acetate and drostanolone propionate at 100 each contained only testosterone propionate, at 49% of the claimed amount.29 In a set of 40 samples that listed 11 active ingredients, drostanolone propionate among them, 8 did not show the active principle stated on the label; the record does not say which products failed or how many were labelled drostanolone propionate.30
More in Other steroids
References
- World Anti-Doping Agency. World Anti-Doping Code International Standard Prohibited List 2026. In force 1 January 2026. WADA Prohibited List 2026
- Borodi G, Turza A, Bende A. Exploring the Polymorphism of Drostanolone Propionate. Molecules 2020. PMC7145311
- Blackburn CM. Use of 2alpha-methyldihydrotestosterone propionate in treatment of advanced cancer of the breast: a group report. Cancer Chemother Rep 1962. PMID 13869675
- Drings P. [Experiences with drostanolone propionate (Masterid) in metastasizing breast carcinoma]. Ther Ggw 1972. PMID 5029717
- Seay DG, Bradshaw JD, Nicol NT. Clinical experience with dromostanolone propionate (NSC-12198) in breast carcinoma. Cancer Chemother Rep 1972. PMID 5067664
- Bennett MB, Helman P, Palmer P. Hormonal therapy of breast cancer with special reference to Masteril therapy. S Afr Med J 1975. PMID 1242823
- Tauchen J, Jurasek M, Huml L, Rimpelova S. Medicinal Use of Testosterone and Related Steroids Revisited. Molecules 2021. PMC7919692
- Bond P, Smit DL, de Ronde W. Anabolic-androgenic steroids: How do they work and what are the risks? Front Endocrinol 2022. PMC9837614
- de Boer D, de Jong EG, Maes RA, van Rossum JM. The methyl-5 alpha-dihydrotestosterones mesterolone and drostanolone; gas chromatographic/mass spectrometric characterization of the urinary metabolites. J Steroid Biochem Mol Biol 1992. PMID 1606052
- Gauthier J, Goudreault D, Poirier D, Ayotte C. Identification of drostanolone and 17-methyldrostanolone metabolites produced by cryopreserved human hepatocytes. Steroids 2009. PMID 19056412
- Liu Y, Lu J, Yang S, Zhang Q, Xu Y. New drostanolone metabolites in human urine by liquid chromatography time-of-flight tandem mass spectrometry and their application for doping control. Steroids 2016. PMID 26826321
- Baranov P, Amosova M, Vukolova M, Pirozhkov S, Lutokhina Y. Regression of Anabolic-Androgenic Steroid-Associated Cardiomyopathy Eight Years After Cessation of Anabolic-Androgenic Steroid Abuse: A Case Report and Literature Review. J Clin Med 2026. PMC13665845
- Wiacek M, Trabka B, Tomasiuk R, Zubrzycki IZ. Changes in Health-related Parameters Associated with Sports Performance Enhancement Drugs. Int J Sports Med 2023. PMC10049838
- Clavel B, Cappelaere JP, Guerin J, et al. Management of advanced breast cancer in post-menopausal women. A comparative trial of hormonal therapy, chemotherapy, and a combination of both. Sem Hop 1982. PMID 6293073
- Rieche K, Wolff G. Comparison of testosterone decanoate, drostanolone and testololactone in disseminated breast cancer: a randomized clinical study. Arch Geschwulstforsch 1975. PMID 1243528
- Wolff G, Rieche K. Androgen therapy of incurable breast neoplasms. Controlled clinical study: nandrolone-testololactone-drostanolone. Onkologie 1978. PMID 362297
- Azen EA, Shahidi NT. Androgen dependency in acquired aplastic anemia. Am J Med 1977. PMID 578075
- Gaertner RA, Lewison EF, Finney GG, Montague AC. Combined hormone therapy in advanced breast cancer. Triple-blind study of 68 patients treated with dromostanolone and fluorometholone. Johns Hopkins Med J 1968. PMID 4876823
- Helman P, Bennett MB. Hormone therapy of breast cancer with special reference to masteril therapy. S Afr Med J 1972. PMID 5068714
- Poddig-von Riegen S. [Treatment of disseminated mammary carcinoma with drostanolone propionate (Masterid). Report on 22 treated cases]. Munch Med Wochenschr 1971. PMID 5108667
- Chowdhury MS, Banks AJ, Bond WH, Jones WG, Ward HW. A comparison of drostanolone propionate (Masteril) and nandrolone decanoate (Deca-durabolin) in the treatment of breast carcinoma. Clin Oncol 1976. PMID 1036981
- Marinov L, Tsekova V, Koinov K, Velikova M, Micheva D. [Drostanolone propionate (masteril) in disseminated breast cancer in women. Immediate results]. Khirurgiia (Sofiia) 1987. PMID 2830431
- Ozkurt S, Ozakin E, Gungor H, Yalcin AU. Assessment of Renal Function of Bodybuilders Using Anabolic Androgenic Steroids and Diet Supplements. Cureus 2023. PMC10481367
- Safizadeh Shabestari SA, Ho SB, Chaudhary P, Nathwani RA. Drug-induced acute pancreatitis in a bodybuilder: a case report. J Med Case Rep 2022. PMC8939103
- Gheddar L, Blanchot A, Ameline A, et al. The Power of Keratinous Matrices (Head Hair, Body Hair and Nail Clippings) Analysis in a Case of Death Involving Anabolic Agents. J Anal Toxicol 2023. PMID 36516229
- Albertsdottir AD, Van Gansbeke W, Coppieters G, et al. Searching for new long-term urinary metabolites of metenolone and drostanolone using gas chromatography-mass spectrometry with a focus on non-hydrolysed sulfates. Drug Test Anal 2020. PMID 32386339
- Kintz P, Gheddar L, Raul JS. Testing for anabolic steroids in human nail clippings. J Forensic Sci 2021. PMID 33885144
- Favretto D, Stocchero G, Pertile R, et al. Post-mortem investigation into a death involving doping agents: The case of a body builder. Drug Test Anal 2022. PMC9804486
- Balayssac S, Assemat G, Danoun S, Malet-Martino M, Gilard V. Quantitative 1H and 13C NMR and Chemometric Assessment of 13C NMR Data: Application to Anabolic Steroid Formulations. Molecules 2025. PMC12074264
- Ribeiro MVM, Boralle N, Felippe LG, Pezza HR, Pezza L. 1H NMR determination of adulteration of anabolic steroids in seized drugs. Steroids 2018. PMID 30003910
- Teller MN, Stock CC, Bowie M, Chou TC, Budinger JM. Therapy of 7,12-dimethylbenz(a)anthracene-induced rat mammary carcinomas with combinations of 5-fluorouracil and 2 alpha-methyldihydrotestosterone propionate. Cancer Res 1982. PMID 6812946
- Fujita H, Teller MN, Green S, Kreis W. Effects of 5-fluorouracil and 2 alpha-methyldihydrotestosterone propionate on the growth of human breast carcinoma MCF-7 in vitro. Eur J Cancer Clin Oncol 1983. PMID 6688585
- US Drug Enforcement Administration. 21 CFR 1308.13, Schedule III. Electronic Code of Federal Regulations. 21 CFR 1308.13
- Trams G. Effect of drostanolone propionate on the binding of oestradiol and dihydrotestosterone by normal and malignant target tissues. Eur J Cancer 1977. PMID 576855
- US National Library of Medicine. DailyMed web services, search by drug name for drostanolone, dromostanolone and masteron, 16 November 2026. DailyMed search